Physician profile
Millicent Nowak
NPI 1285223420
$13,478.36
in general payments reported to CMS, 2019-2025
38 companies · $5,706 in 2025
The $5,706 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $604 · 2023: $2,250 · 2024: $4,450 · 2025: $5,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,125 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,922.84 |
| Consulting Fee | $1,125.00 |
| Education | $358.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,357.45 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,459.03 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,252.44 | 2023-2025 | |
| Genzyme Corporation | $1,053.67 | 2023-2025 | |
| Incyte Corporation | $875.37 | 2023-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $842.73 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $764.07 | 2021-2025 | Sotyktu |
| Lilly USA, LLC | $573.99 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $405.20 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $365.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $299.62 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $288.10 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $261.23 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Mayne Pharma Commercial LLC | $249.25 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $242.47 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $237.86 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $227.19 | 2024-2025 | Tremfya |
| Inari Medical, INC. | $214.22 | 2021 | |
| Convatec INC. | $208.88 | 2023 | |
| Dermavant Sciences, INC. | $205.43 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.53 | 2021-2025 | Spevigo, Cyltezo |
| Boston Scientific Corporation | $183.75 | 2022 | |
| Abbott Laboratories | $148.18 | 2022 | |
| Journey Medical Corporation | $105.63 | 2023-2025 | |
| Organon LLC | $101.75 | 2025 | Vtama |
| Impulse Dynamics (USA) INC. | $89.27 | 2022 | |
| Biofrontera INC. | $65.01 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.41 | 2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $32.35 | 2023-2024 | Ycanth |
| Organogenesis INC. | $27.31 | 2024 | |
| Mimedx Group, INC. | $20.47 | 2024 | |
| Almirall LLC | $16.85 | 2024 | Klisyri |
| Angiodynamics, INC. | $16.63 | 2021 | |
| Genentech USA, INC. | $14.87 | 2023 | Erivedge |
| Paratek Pharmaceuticals, INC. | $14.58 | 2025 | Nuzyra |
| Cgg Medical INC | $14.51 | 2024 | |
| Tactile Systems Technology INC | $14.41 | 2025 | Nimbl, Flexitouch Plus |
| Kerecis Limited | $5.80 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Nowak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.